It is grim, but the average does not tell the whole story. From what I understand, it extends the life of several patients for a long time, with 4x more patients surviving three years after diagnosis. The average is low because, just as with most cancer drugs, it only helps a percentage of the patients.
1.6 month increased average survival. Spin it and slice the numbers however they want to, thats still pretty grim.
It is grim, but the average does not tell the whole story. From what I understand, it extends the life of several patients for a long time, with 4x more patients surviving three years after diagnosis. The average is low because, just as with most cancer drugs, it only helps a percentage of the patients.